CYP2C19 extensively metabolizes citalopram and escitalopram to much less potent metabolites. Patients may be predisposed to poor therapeutic outcomes due to having CYP2C19 allelic variants that alter antidepressant biotransformation. To minimize unfavorable clinical outcomes with citalopram, escitalopram, or sertraline, a clinically appropriate alternative antidepressant not extensively metabolized by CYP2C19 is recommended in CYP2C19 poor metabolizers, or dose adjustments can be considered.

The guideline states that CYP2C19 poor and likely poor metabolizers have "greatly reduced metabolism" or "reduced metabolism" of citalopram, escitalopram and sertraline to less active compounds compared with normal metabolizers, and that "higher plasma concentrations may increase the probability of side effects." It recommends that clinicians "consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19" or, if citalopram or escitalopram are used, to use a "lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose" compared to normal metabolizers. It also notes that for citalopram "the FDA recommends a 50% dose reduction (or a maximum dose of 20 mg/day in adults) for CYP2C19 PMs due to the risk of QT prolongation."

Both reduced and increased CYP2C19 activity were associated with higher switching rates. Ultrarapid metabolizers showed a reduced time to dose escalation and a reduced time to switching compared with normal metabolizers, while reduced-function groups also showed poorer treatment persistence.

The association of CYP2C19 metabolic phenotypes with clinically evaluated treatment response was performed to investigate whether genotype-determined PMs, IMs, and RMs/UMs showed differential antidepressant efficacy, compared to NMs. Overall, PMs in CYP2C19 showed a higher remission rate with nominal significance (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033) but did not meet correction for multiple testing. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. In conclusion, using imputed genotype data, our meta-analysis showed no significant association between CYP2C19 metabolic phenotypes with antidepressant response.

Across studies of antidepressant treatment, reduced-function CYP2C19 phenotypes were associated with altered exposure to several SSRIs, especially citalopram and escitalopram, and with differences in clinical outcomes including response, remission, switching, and discontinuation. The authors concluded that CYP2C19 contributes to variability in antidepressant effectiveness.

CPIC defines CYP2C19 poor metabolizers as having "greatly reduced metabolism when compared to extensive metabolizers" and notes that "higher plasma concentrations may increase the probability of side effects." For these patients, it recommends to "consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19." The guideline specifically states that pharmacokinetic data show "reduced oral clearance of sertraline in CYP2C19 poor metabolizers" and that side effects have been reported to be more frequent in CYP2C19 poor metabolizers than in normal metabolizers, leading to a recommendation for a 50% sertraline dose reduction or use of an alternative SSRI not extensively metabolized by CYP2C19.

In the dosing recommendations table, CYP2C19 poor metabolizers for citalopram, escitalopram and sertraline are described as having "greatly reduced metabolism" to less active compounds compared with CYP2C19 normal metabolizers, with the comment that "higher plasma concentrations may increase the probability of side effects." The guideline recommends that if citalopram, escitalopram or sertraline is clinically indicated in CYP2C19 poor metabolizers, clinicians should use "a lower starting dose, slower titration, and a 50% reduction of standard maintenance doses" or consider an antidepressant not predominantly metabolized by CYP2C19. It reiterates that, per FDA labeling, "citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation."

One study suggested that the CYP2C19 poor metabolism phenotype is more prevalent in treatment resistant bipolar disorder compared with major depressive disorder (MDD). In a large study of the impact of CYP2C19 metabolic phenotypes on antidepressant treatment of bipolar depression, we found an association between slower CYP2C19 metabolism and higher risk of treatment emergent mania. There were, however, no clear associations with early treatment persistence, treatment discontinuation, and switching to a new antidepressant.

This study evaluated PK and PD genetic variation and the clinical use of such testing in treatment seeking patients with bipolar disorder (BP) and major depressive disorder (MDD) and history of multiple drug failures/treatment resistance. There were significantly more CYP2C19 poor metabolizer (PM) phenotypes in BP (9.3%) vs. MDD patients (1.7%, p = 0.003); among participants with an S-allele, the rate of CYP2C19 PM phenotype was even higher in the BP (9.8%) vs. MDD (0.6%, p = 0.003). Conclusion: There may be underlying pharmacogenomic differences in treatment seeking depressed patients that potentially have impact on serum levels of CYP2C19-metabolized antidepressants (i.e., citalopram/escitalopram) contributing to rates of efficacy vs. side effect burden with additional potential risk of antidepressant response vs. induced mania.

These CPIC guidelines provide dosing recommendations for citalopram, escitalopram, and sertraline based on CYP2C19 genotype. For CYP2C19 poor metabolisers, the guideline recommends considering alternative SSRIs not predominantly metabolised by CYP2C19 or a 50% dose reduction, because poor metabolisers can have greatly increased plasma concentrations, increasing the risk of adverse drug reactions and treatment discontinuation. The guidelines note that failure to adjust dosing in poor metabolisers may result in side effects and nonadherence that could be interpreted clinically as lack of efficacy.

The CYP2C19 enzyme, involved in metabolizing certain antidepressants, can influence treatment response. Genetic polymorphisms and epigenetic changes in the CYP2B6, CYP2D6, CYP3A4, and CYP2C19 genes significantly influence the metabolism of antidepressant and antipsychotic drugs and may be responsible for interethnic and interindividual variations in drug therapeutic efficacy. These findings suggest that CYP2C19 polymorphisms may influence the metabolism of some antidepressants but not others, highlighting the need to tailor pharmacotherapy to genetic background. Despite some common findings, inconsistencies highlight the need for further research to clarify the role of these polymorphisms in MDD and optimize treatment strategies.

We tested whether symptom improvement, response, and side effects were associated with CYP2C19 metabolic status while adjusting for potential confounders. The study specifically evaluated whether CYP2C19 metabolizing status was linked to differential antidepressant outcomes in routine depression treatment.

We investigated the effect of CYP2C19 metaboliser status on antidepressant response and side-effects in patients treated with citalopram or escitalopram. Compared with extensive metabolisers, poor metabolisers had higher plasma concentrations and showed a higher probability of remission but also a higher risk of side-effects at standard doses. The authors conclude that CYP2C19 poor metabolisers may benefit from lower doses of citalopram/escitalopram to optimise the balance between efficacy and tolerability.

CYP2C19 is a fundamental enzyme in the metabolism of antidepressants, whose genetic variability is associated with treatment resistance, and advocates for the implementation of pharmacogenetic testing to personalize therapy (Zhiganova and Radkova, 2025). Li et al. (2024) revealed that CYP2C19 poor metabolizers exhibited a higher remission rate compared to normal metabolizers (OR = 1.46; 95% CI = 1.03–2.06; p = 0.033), suggesting that reduced metabolic capacity might lead to higher systemic exposure to active drug forms, thereby enhancing antidepressant efficacy. The authors noted that poor or intermediate metabolizers demonstrate reduced drug clearance, which can elevate systemic exposure and increase ADR risk, whereas rapid or ultrarapid metabolizers may experience subtherapeutic exposure and treatment failure. Empirical evidence suggested that roughly 60% of antidepressant-related adverse or ineffective responses could be linked to actionable genotypes, corroborating the predictive validity of pharmacogenetic profiling.

A common novel CYP2C19 gene variant, CYP2C19*17, was identified that confers ultrarapid CYP2C19 activity. Conclusion: CYP2C19*17 is likely to cause therapeutic failures in drug treatment with, for example, proton pump inhibitors and antidepressants. Predictions revealed that CYP2C19*17 homozygotes would attain 35% to 40% lower omeprazole area under the plasma concentration-time curve values than subjects homozygous for CYP2C19*1 taking standard doses.

CYP2C19 is a clinically important drug-metabolizing enzyme. Genetic variation in CYP2C19 can significantly influence drug metabolism and clinical outcomes, and the gene is used in pharmacogenetic interpretation for multiple medications, including antidepressants and antiplatelet drugs.

This systematic review and meta-analysis of 94 studies including 8379 patients found that CYP2C19 and CYP2D6 poor and intermediate metabolizer status was significantly associated with altered antidepressant and antipsychotic plasma concentrations. For escitalopram and sertraline, CYP2C19 poor metabolizers had 3.3-fold (95% CI, 2.2- to 5.0-fold) and 2.7-fold (95% CI, 2.0- to 3.6-fold) higher concentrations, respectively, compared with normal metabolizers. Such gene-associated alterations in exposure can lead to an increase of incidence or severity of adverse drug reactions or lack of response.

The authors note that current CPIC guidelines report CYP2C19 poor metabolizers "to be at increased risk of adverse side-effects due to higher antidepressant serum concentrations" and that ultrarapid metabolizers are hypothesized to be more likely to fail therapy due to decreased exposure. In their own data, "poor metabolisers showed a nominally significant higher antidepressant efficacy (OR = 1.41 [1.02–1.95] p = 0.037)" overall, with a similar result for sertraline, although these associations did not remain significant after correction for multiple testing. They also report that CYP2C19 intermediate metabolizers had higher odds of reporting more side effects, and conclude that they "found evidence for an association between slower CYP2C19 metabolism and adverse side effects," consistent with the guideline hypothesis about altered exposure and tolerability.

The overview page summarising the meta-analysis notes that CYP2C19 poor metabolisers could potentially contribute to antidepressant efficacy, with more evidence needed. It highlights that sequencing and targeted pharmacogenetic testing of CYP2C19 can inform dosing of certain antidepressants such as citalopram and escitalopram, which are mainly metabolised by CYP2C19. Linked items on this page also reference case reports and studies where CYP2C19 variants were associated with altered antidepressant response or nonresponse.

Among 5843 depression patients, a higher remission rate was found in CYP2C19 poor metabolizers compared to normal metabolizers at nominal significance but did not survive after multiple testing correction (OR = 1.46, 95% CI [1.03, 2.06], p = 0.033). No metabolic phenotype was associated with percentage improvement from baseline. After stratifying by antidepressants primarily metabolized by CYP2C19, no association was found between metabolic phenotypes and antidepressant response. In conclusion, metabolic phenotypes imputed from genetic variants using genotype were not associated with antidepressant response.

The full PDF reiterates that "genetic variation in CYP2D6, CYP2C19, and CYP2B6 influences the metabolism of many of these antidepressants, which may potentially affect dosing, efficacy, and tolerability." For CYP2C19 poor metabolizers on citalopram, escitalopram, or sertraline, it describes "greatly reduced metabolism" and "higher plasma concentrations" and again recommends consideration of an alternative antidepressant not predominately metabolized by CYP2C19 or a 50% reduction in standard maintenance dose with careful titration. These recommendations are framed as a way to avoid adverse outcomes related to altered exposure rather than as evidence that poor metabolizers have reduced antidepressant efficacy.

Many antidepressants are substrates of CYP2D6 and CYP2C19, and genetic polymorphisms in these enzymes can markedly alter serum concentrations. The review states that poor metabolisers for CYP2D6 or CYP2C19 are at increased risk of adverse effects when treated with standard doses of drugs metabolised by the affected enzyme, which may lead to discontinuation and apparent treatment resistance. It notes specifically that citalopram and escitalopram are predominantly metabolised by CYP2C19 and that genotype-guided dosing has been proposed to reduce side effects and improve adherence.

Patients with two loss-of-function CYP2C19 alleles have significantly decreased enzyme activity. One loss-of-function CYP2C19 allele also confers reduced enzyme activity. Although this page focuses on clopidogrel, it documents the functional meaning of CYP2C19 loss-of-function alleles as reduced enzyme activity.

This study evaluated the relationship between CYP2C19 genotype, escitalopram plasma levels, and clinical outcome. CYP2C19 poor metabolisers had significantly higher escitalopram concentrations at standard doses compared with extensive metabolisers. Higher plasma levels were associated with more frequent adverse effects and treatment discontinuation, while there was no consistent advantage in symptom improvement, suggesting that reduced CYP2C19 activity can impair tolerability without clearly improving efficacy.

This meta-analysis investigated whether CYP2C19 metabolizing activity is associated with antidepressant response and side effects. Across 2558 patients treated primarily with citalopram or escitalopram, we found no significant association between CYP2C19 metabolic activity and antidepressant response. However, CYP2C19 poor metabolizers had a higher risk of certain side effects, consistent with higher drug exposure, whereas ultrarapid metabolizers tended to have lower plasma concentrations that might predispose to non-response.

In this naturalistic study of patients treated with antidepressants and antipsychotics, genotyping for CYP2D6 and CYP2C19 was used to adjust therapy. Patients whose medication was guided by their CYP2D6/CYP2C19 genotype had significantly greater improvement in clinical global impression and fewer adverse effects compared with unguided patients. The authors suggest that identifying poor metabolisers and avoiding or dose-adjusting drugs for which they have reduced metabolic capacity may prevent side effects and nonresponse that can be misinterpreted as treatment-resistant illness.

This longitudinal study reported that almost half (46.7%) of MDD out-patients received a CYP2D6/CYP2C19 phenotype–drug mismatch. Such mismatch, defined as prescribing an antidepressant primarily metabolised by an enzyme for which the patient had reduced or increased activity, was linked to a reduction in HAM-D improvement and higher rates of side effects over follow-up. The authors conclude that avoiding phenotype–drug mismatches, particularly in poor and ultra-rapid metabolisers, may improve antidepressant effectiveness and prevent apparent treatment resistance.

The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for citalopram and escitalopram recommends dose adjustments based on CYP2C19 phenotype. For CYP2C19 poor metabolizers, CPIC recommends a 50% reduction of the standard starting dose or selecting an alternative antidepressant, due to higher plasma concentrations and increased risk of side effects. For CYP2C19 ultrarapid metabolizers, CPIC states that there is a risk of subtherapeutic concentrations and recommends considering an alternative antidepressant not predominantly metabolized by CYP2C19.

Scientific literature has never described a poor metabolizer for both the cytochrome P450 (CYP) 2D6 and the CYP 2C19. They are expected to be rare (<1% in different ethnic groups) and prone to adverse drug reactions with many antidepressants. The naturalistic antidepressant treatment of this poor metabolizer for both enzymes is described in this article, highlighting intolerance to several standard antidepressants and better tolerability with mirtazapine, which is less dependent on these enzymes.

In this study, escitalopram serum concentrations and clinical outcomes were analyzed according to CYP2C19 genotype. Patients who were CYP2C19 poor metabolizers had significantly higher escitalopram plasma concentrations and more frequent adverse effects, leading more often to treatment discontinuation, whereas CYP2C19 ultrarapid metabolizers exhibited lower concentrations and an increased rate of therapeutic failure. These findings support that CYP2C19 loss-of-function and gain-of-function variants predominantly affect drug exposure and tolerability, with non-response more common in ultrarapid metabolizers.

This CPIC-based annotation for tricyclic antidepressants states that "if amitriptyline is warranted, consider a 50% dose reduction in CYP2D6 or CYP2C19 poor metabolizers." The underlying principle is that decreased CYP2C19 activity reduces metabolic clearance of amitriptyline, resulting in higher plasma levels and a need for lower starting doses or alternative drugs to avoid toxicity while maintaining effect.

The article discusses how pharmacogenetic decision support tools, including CYP2C19 status, can be used to individualize antidepressant prescribing. It notes that patients with multiple failed antidepressant trials are more likely to carry unusual metabolizer phenotypes (such as poor or ultra-rapid status) that lead to either subtherapeutic or supratherapeutic drug levels at standard doses. These pharmacokinetic mismatches can manifest clinically as apparent treatment resistance or intolerance, and adjusting therapy based on CYP2C19 and CYP2D6 genotypes may reduce these problems.

Citalopram and escitalopram are metabolized primarily by CYP2C19 and CYP3A4. Individuals who are CYP2C19 poor metabolizers have greatly reduced clearance of these drugs, resulting in higher plasma concentrations and increased risk of dose-dependent adverse effects, such as QT prolongation. Conversely, CYP2C19 ultrarapid metabolizers may have lower than expected plasma concentrations, which can lead to reduced drug efficacy and possible treatment failure.

Certain patients carry CYP2C19 or CYP2D6 loss-of-function alleles which causes slower metabolism and subsequent elevation in drug exposure, leading to increased adverse drug reactions. The study showed clinically relevant alterations in exposure for the antipsychotic drugs risperidone, aripiprazole, and haloperidol in relation to the patient’s CYP2D6 genotype as well as similar alterations of escitalopram and sertraline exposure in relation to the patient’s CYP2C19 genotype. Such gene-associated alterations in exposure can lead to the increase of incidence or severity of adverse drug reactions or lack of response; however, knowledge of the patient’s genotype can individualize the drug treatment resulting in better therapeutic effects.

Many antidepressant drugs are partially metabolized through CYP2C19, which affects the efficacy of treatment as well as the risk of side effects. The document states that CYP2C19 variants affect metabolism of many clinically important drugs and notes that CYP2C19 poor metabolizers may have worse outcomes when standard doses are used for some antidepressants.

Reduced metabolism when compared to CYP2C19 normal metabolizers. Higher plasma concentrations may increase the probability of side effects. Initiate therapy with recommended starting dose. The annotation indicates that CYP2C19 genotype can affect antidepressant exposure and tolerability.

In this official CPIC educational video, the presenter explains that for sertraline, "a dose reduction and slower titration schedule should also be considered for patients who are CYP2C19 poor or likely poor metabolizers" because they will have "greatly reduced metabolism of sertraline compared to normal metabolizers" and "may also have an increased probability of experiencing side effects." The recommended action is that a "lower starting dose, slower titration schedule and a 50% reduction of the standard maintenance dose should be considered" or that a clinically appropriate antidepressant not predominantly metabolized by CYP2C19 can be selected.

In pharmacogenetic guidelines, CYP2C19 reduced-function and poor-metabolizer phenotypes are associated with reduced clearance of citalopram and escitalopram, which can raise plasma concentrations and contribute to nonresponse or treatment changes in some patients. This is the biological rationale behind CPIC recommendations to consider alternative antidepressants or dose adjustments.